

72.0 Gy in 42 fractions/6 weeks). The primary endpoint was the treatment completion rate of patients who completed $\geq 70\%$ of the cetuximab planned dose administration (in terms of the relative dose intensity of cetuximab) and the full dose of radiotherapy ≤ 2 weeks over the planned schedule (in terms of radiotherapy duration ≤ 8 weeks).

Results: From Mar 2009 until Jan 2010, 27 pts were screened. Of them, 22 pts were enrolled and treated (ITT population). Patients characteristics of ITT population: median age (years), 67.0 (range, 53 to 81); male/female, 21/1 pts; oropharynx/hypopharynx/larynx, 6/8/8 pts; stage III/IV, 12/10 pts. The median duration of cetuximab treatment was 7.9 weeks (range, 7 to 9), and that of RT was 44.0 days (range, 40 to 52). All 22 pts completed the treatment, and the completion rate was 100% (95% CI: 84.6%, 100.0%). The response rate (CR+PR) post RT was 81.8% (assessed by the independent committee). All pts experienced AEs. Most common AEs with grade 3/4 were mucosal inflammation (16pts, 72.7%), dermatitis (6pts, 27.3%), infection, radiation skin injury and stomatitis (each in 5 pts, 22.7%).

Conclusions: The completion rate (100%) and the response rate (81.8%) are comparable to those of the cetuximab + RT group in the multinational randomized phase III study (Bonner et al. 2006). AEs were consistent with the underlying disease, administration of RT or cetuximab. The study results demonstrate that cetuximab + RT is well-tolerated, a feasible and efficacious treatment in Japanese pts.

8571

POSTER

Helical Tomotherapy in the Treatment of Locally Advanced Squamous Cell Oral Carcinoma

M. Cianciulli¹, C. Caruso¹, A. Monaco¹, A. Rocco², L. Vigna³, R. Rauco⁴, V. Donato¹. ¹Azienda Ospedaliera San Camillo-Forlanini, Radioterapia, Roma, Italy; ²Azienda Ospedaliera San Camillo-Forlanini, Otorinolaringoiatria, Roma, Italy; ³Azienda Ospedaliera San Camillo-Forlanini, Oncologia Medica, Roma, Italy; ⁴Azienda Ospedaliera San Camillo-Forlanini, Fisica sanitaria, Roma, Italy

Background: The aim of this study is the evaluation of toxicity and response to the treatment of patients affected with locally advanced carcinoma of the oral cavity, irradiated by Helical Tomotherapy.

Materials and Methods: From February 2008 to January 2011, 87 patients with head-neck cancer were treated by Helical Tomotherapy. Among them, 20 presented locally advanced squamous cell carcinoma of the oral cavity and were treated with radical intent: 12 underwent concomitant radiochemotherapy with weekly administration of Carboplatin and 8 exclusive radiotherapy for comorbidities.

Median age was 67 years (39–87) and male/female ratio 3:1. Regarding anatomic subsite, oral tongue, floor of the mouth, gingiva, retromolar trigone primary tumours, were 8, 6, 1, 5, respectively. Stage of disease at diagnosis was III in 2, IVA in 16 and IVB in 2 cases.

Simultaneous Integrated Boost (SIB) technique in 30 fractions was used, delivering 66 Gy (RT-CT)/67.5 Gy (RT) to PTV1 (PET positive oral region), 60–63 Gy to PTV2 (oral cavity and PET positive nodes), 54 Gy to PTV3 (negative cervical nodes). Contouring was performed on the basis of a CT/PET/MR image fusion. Planned Adaptive module was used in consideration of anatomical changes occurred during the therapy.

Results: All patients completed radiotherapy, without any interruption due to the treatment. Concerning acute toxicity, G2 dermatitis, dysphagia and mucositis were registered in 25%, 40% and 55% of cases, respectively. Median follow up was 16 months (range 3–29). Response on primary tumour and positive nodes was achieved in all patients, in terms of clinical and nuclear/radiological findings: complete in 16 (80%) and partial in 4 (20%). One year after the end of the treatment, no significant difference between RT-CT and RT was noted.

Conclusion: Helical Tomotherapy allows to obtain favourable local control and low acute toxicity in locally advanced squamous cell carcinoma of the oral cavity.

8572

POSTER

Results of Postoperative Radiotherapy in Patients With Salivary Duct Carcinoma of the Major Salivary Glands

J. Kim¹, S. Lee², K. Cho³, S. Kim⁴, S. Nam⁴, S. Choi⁴, J. Roh⁴, E. Choi², H. Shin¹, S. Chang¹. ¹CHA Bundang Medical Center CHA University, Radiation Oncology, Gyeonggi, Korea; ²University of Ulsan College of Medicine Asan Medical Center, Radiation Oncology, Seoul, Korea; ³University of Ulsan College of Medicine Asan Medical Center, Pathology, Seoul, Korea; ⁴University of Ulsan College of Medicine Asan Medical Center, Otolaryngology, Seoul, Korea

Background and Purpose: Salivary duct carcinoma (SDC) is a rare malignancy of high grade pathologic type. Currently, there are no confirmed prognostic variables in the management of SDC. We evaluated clinical

outcomes and prognostic factors in 35 patients with SDC treated with postoperative adjuvant radiation, and investigated postoperative adjuvant RT role.

Materials and Methods: We retrospectively assessed overall survival (OS), locoregional control (LRC), and disease-free survival (DFS) in 35 patients with SDC of the major salivary glands who underwent surgery. Neck dissection was performed in 31 patients (88.6%). All patients received postoperative adjuvant RT to tumour bed and ipsilateral neck node. Prescribed median dose was 59.4 Gy (range, 50.4–71.4 Gy). Factors evaluated for prognosis included gender, age, symptom duration, tumour site, tumour size, TNM classification, and pathologic features; perineural invasion (PNI), lymphovascular invasion (LVI), extra-parenchymal invasion, and resection margin status. The median follow-up period was 43 months (range, 7–155 months).

Results: Of the 35 patients, 30 (85.7%) were male: median age at initial diagnosis was 62 years (range, 38–75 years). The parotid gland was mainly affected in 22 patients (62.9%). Eighteen patients (51.5%) had pathologic T3/T4 tumours, and 26 patients (74.3%) showed pathologic nodal involvement. The actuarial 3-year locoregional control, disease-free survival, overall survival rates were 75.8%, 55.7%, and 79.5%, respectively. Cause specific death rate was 31.4% (n = 11). Pathologic nodal involvement was correlated with distant metastasis ($p = 0.011$). Lymphovascular invasion was significant prognostic factor of distant metastasis-free survival ($p = 0.049$), locoregional control ($p = 0.012$), and overall survival ($p = 0.003$) in the Cox proportional hazard model, whereas perineural invasion was significant prognostic factor only of overall survival ($p = 0.005$).

Conclusions: Despite high nodal involvement rate, loco-regional control was successful. Surgery and postoperative radiotherapy were effective for locoregional control. Lymphovascular invasion and perineural invasion were significant prognostic factors for patients with SDC.

8573

POSTER

Treatment Outcomes of Radiotherapy for Tonsillar Carcinoma in the Era of Intensity-modulated Radiotherapy

T.R. Koo¹, H.G. Wu¹, K.H. Kim², M.W. Sung², C.I. Park¹. ¹Seoul National University Hospital, Department of Radiation Oncology, Seoul, Korea; ²Seoul National University Hospital, Department of Otorhinolaryngology, Seoul, Korea

Background: We performed this study to analyze treatment outcomes and to evaluate prognostic factors in patients with tonsillar carcinoma who were treated with radiotherapy (RT).

Materials and Methods: We retrospectively reviewed 164 patients with tonsillar carcinoma treated with RT between January 1979 and September 2009. Of the 164 patients, 91 were treated with 2-dimensional RT (2D-RT), 46 were treated with 3-dimensional conformal RT (3D-CRT), and 27 were treated with intensity-modulated RT (IMRT). When patients were treated with IMRT, simultaneous integrated boost was used. Thirty patients were treated with RT alone, 40 patients were treated with chemotherapy and RT (CRT), 66 patients were treated with surgery and RT and/or chemotherapy (SRT), and 28 patients were treated with concurrent chemoradiotherapy (CCRT). Bilateral neck irradiation was delivered to 141 patients, and ipsilateral neck irradiation to 23 patients. In definitive RT, median dose was 70 Gy (range, 51–71), 70 Gy (54–74), and 67.5 Gy for 2D-RT, 3D-CRT, and IMRT, respectively. In postoperative RT, median dose was 64.8 Gy (range, 54–70.2), 66 Gy (54–70), and 63 Gy (60–67.5) for 2D-RT, 3D-CRT, and IMRT, respectively. Acute and late toxicity were graded according to the Radiation Therapy Oncology Group radiation morbidity scoring criteria.

Results: The median follow-up time was 42 months (range, 2–288). The 5-year locoregional progression-free survival (LRPFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS) rates were 86%, 94%, 82%, and 80%, respectively. In the univariate analysis, 5-year DFS rate was associated with the RT technique (2D-RT, 77%; 3D-CRT, 82%; IMRT, 100%, $p = 0.035$), T stage (T1–2, 87%; T3–4, 74%, $p = 0.036$), and treatment modality (RT alone, 55%; CRT, 78%; SRT, 92%; CCRT, 92%, $p < 0.0001$). In the multivariate analysis, advanced T stage and treatment modality were statistically significant prognostic factors in DFS rate. None of the patients who were treated with ipsilateral neck irradiation experienced relapse in contralateral neck nodes. After the completion of RT, patients who were treated with 2D-RT, 3D-CRT, IMRT, ipsilateral neck irradiation, and bilateral neck irradiation experienced grade ≥ 2 xerostomia 91%, 58%, 59%, 35%, and 78%, respectively. At least 6 months of follow-up, patients who were treated with 2D-RT, 3D-CRT, IMRT, ipsilateral neck irradiation, and bilateral neck irradiation experienced grade ≤ 1 xerostomia 52%, 76%, 78%, 98%, and 63%, respectively.

Conclusions: In selected patients with well lateralized tonsillar carcinoma, ipsilateral neck irradiation can be an alternative to bilateral neck irradiation, regarding DFS rate and complications. There was no failure when patients were treated with IMRT, but long-term follow-up is needed to evaluate the